Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, according to researchers. In a trial where cancers were treated with chemotherapy ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ ...

Treating patients with a drug before surgery greatly reduced the chances of the cancer coming back, a small trial found.

LISTEN: Price caps lead to shortages. Want to reduce costs? Allow drug companies to sell directly and eliminate the middlemen ...

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Obicetrapib monotherapy significantly improved the lipid profile of patients with heterozygous familial hypercholesterolemia ...